Could Novavax Be Too Late to the Party to Win in the U.S. COVID Vaccine Market?

1 min read

Novavax (NASDAQ: NVAX) seems to be on its way toward winning U.S. Emergency Use Authorization (EUA) for its COVID-19 vaccine within the next few months. However, the biotech’s vaccine is likely to be the fifth one available to Americans. In this Motley Fool Live video recorded on March 24, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Novavax could be too late to the party to win in the U.S. market.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Lululemon Athletica (LULU) Q4 2020 Earnings Call Transcript

Next Story

What’s Behind Harvest Health’s Mixed Q4 Results

Latest from Blog